Oncology

Ipsen’s commitment to oncology is highlighted by its growing portfolio of key therapies that improve the care of patients with prostate cancer, bladder cancer, neuroendocrine tumors, or other niche oncology diseases.

A focused strategy

Focusing on these selected oncology diseases, Ipsen aims to provide fully integrated patient care, contribute to improved diagnosis and provide treatment options tailored to patient needs along with targeted support services. In particular, Ipsen aims to become a leader in the treatment of neuroendocrine tumors and to improve patient outcomes at each stage of the disease. A major step toward this goal was the launch of Somatuline® in 2015 as a treatment for gastroenteropancreatic tumors in the United States and in 2016 in Europe. These approvals were based on the landmark CLARINET® study demonstrating the antitumor effect of Somatuline® to reduce the risk of disease progression or death by 53% in patients with gastroenteropancreatic neuroendocrine tumors.

A leader in neuroendocrine tumors

In addition to Somatuline®, Ipsen’s leadership in NETs will be further reinforced with the anticipated launches of telotristat etiprate (ex. US) in the next years as a treatment for symptom control in combination with somatostatin analog for patients with carcinoid syndrome, in partnership with Lexicon Pharmaceuticals.

Moreover, in October 2015, Ipsen acquired OctreoPharm Sciences to gain access to new resources to advance diagnosis and treatment of neuroendocrine tumors using radiopharmaceuticals. This new therapeutic expertise has been further reinforced by the licensing agreement from 3B Pharmaceuticals in early 2016 to develop novel radiopharmaceuticals in oncology. This product portfolio will allow the coverage of the full spectrum of neuroendocrine tumor management while providing theranostic solutions to patients.

A strong pipeline

In early 2016, Ipsen bolstered its oncology pipeline with a very important oncology deal with the US company Exelixis. Ipsen acquired (ex-North America and Japan) a potential best in class oral drug with solid scientific data. Cabozantinib has the potential to become a key drug in various oncology indications. Its commercial launch is expected in 2017 in Europe for the second line treatment of kidney cancer as the drug is the first therapy to demonstrate in the METEOR® phase III trial, robust and meaningful improvements in all three key efficacy parameters: overall survival, progression-free survival and objective response rate.

Long lasting partnerships

Ipsen has built its strength in oncology through strong, long-lasting partnerships with research hubs, such as Harvard University or Curie Institute. This long-standing approach resulted in several new key partnerships, such as with Telesta, 3B Pharmaceuticals, Exelixis or Peptimimesis between May 2015 and March 2016.

Ipsen is a key partner of the most important medical societies, in Europe and the United States in urology (EAU, ESOU), in endocrinology (ENETS, ENDO) and in oncology (ESMO, ASCO).

In many countries, the Group cooperates closely with patient groups to raise awareness of its targeted disabling conditions and make progress towards earlier diagnosis. Ipsen also supports initiatives (e.g. Acromegaly Day, World NET Cancer Day) or programs (e.g. IPSEN CARES™ in the United States) to support access of patient to treatment and raise awareness on these diseases. In addition, Ipsen is actively involved in creating networks of experts to promote international dialog between specialists with world experts in the field. Ipsen supports a personalized approach to patient management and launched the 3i Pathways program (identify, individualize, improve) to facilitate decision-making by healthcare professionals and to improve communication among specialized physicians and with patients. It aims at increasing patients’ involvement in the management of their disease.

Our portfolio

Somatuline® is an injectable treatment that is particularly effective in inhibiting the secretion of growth hormone as well as certain hormones secreted in the digestive system, which are respectively involved in two rare conditions: acromegaly and neuroendocrine tumors. Somatuline® is the only somatostatin analogue indicated in EU and US for the treatment of pancreatic and gastrointestinal neuroendocrine tumors. The approval in this indication represents a significant step forward in the treatment of this type of tumors, which are rare and difficult to diagnose.
Decapeptyl® is a synthetic hormone made of triptorelin, decapeptide analog of GnRH (gonadotrophin releasing hormone), an hormone secreted by the hypothalamus. Decapeptyl® is primarily indicated for the hormonal treatment of locally advanced metastatic prostate cancer and is also approved for the treatment of endometriosis, uterine fibroma, precocious puberty and female infertility. This treatment offers now a subcutaneous route of injection, allowing more patients to benefit from Decapeptyl®.
Hexvix® is a photosensitizing agent used in the detection and treatment of bladder cancer. It produces specific fluorescence in the tumor cells in the bladder during a procedure called “cystoscopy”, which involves the examination of the bladder via the urethra. As a result, it improves detection and resection of non-invasive bladder cancer and considerably reduces the risks of incomplete resection of missing a tumor that may not be seen through examination under white light. This technology represents a significant improvement for urologists and their patients.
Updated on 03 June 2016